PMID- 18260867
OWN - NLM
STAT- MEDLINE
DCOM- 20081211
LR  - 20181201
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 47
IP  - 6
DP  - 2007
TI  - [Von Willebrand factor and soluble P-selectin in patients with non ST-Elevation 
      acute coronary syndrome during treatment with glycoprotein IIb/IIIa antagonist 
      eptifibatide].
PG  - 4-9
AB  - Soluble P-selectin (marker of activation of platelets) and von Willebrand factor 
      (marker of activation of endothelium) were measured in 44 patients with non 
      ST-Elevation acute coronary syndrome (NSTEACS) 21 of whom received glycoprotein 
      IIb/IIIa antagonist eptifibatide (two 180 mg/kg boluses with 10 min interval 
      followed by infusion of 2 mcg/kg/min during first 24 hours and 1.3 mcg/kg/min 
      during subsequent 48 hours). Measurements were made within first 2 hours, in 2--3 
      and 10--14 days after development of NSTEACS. During first 2 hours P-selectin 
      content was 1.6 times higher than in healthy donors, but in 2--3 and 10--14 days 
      after onset of NSTEACS it did not differ from normal values. Contrary to 
      P-selectin value of von Willebrand factor was elevated both during first 2 hours 
      (1.3 times) and in 2--3 days (2 times) compared with healthy donors. Some 
      elevation of von Willebrand factor (1.2 times) persisted after 10--14 days after 
      development of NSTEACS. The results obtained have shownd that elevated activity 
      of endothelium persists at least for 2--3 days after onset of NSTEACS, while 
      activity of platelets during this period decreases. In none of temporal points 
      there have been revealed differences in contents of P-selectin and von Willebrand 
      factor between groups of patients receiving and not receiving glycoprotein 
      IIb/IIIa antagonists. No differences were also found between these parameters in 
      groups of patients favorable and unfavorable outcomes (myocardial infarction, 
      angina recurrence) of the disease during 30 days of follow-up.
FAU - Mazaev, A A
AU  - Mazaev AA
FAU - Naimushin, Ia A
AU  - Naimushin IaA
FAU - Khaspekova, S G
AU  - Khaspekova SG
FAU - Golubeva, N V
AU  - Golubeva NV
FAU - Ruda, M Ia
AU  - Ruda MIa
FAU - Mazurov, A V
AU  - Mazurov AV
LA  - rus
PT  - Comparative Study
PT  - Journal Article
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (P-Selectin)
RN  - 0 (Peptides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (von Willebrand Factor)
RN  - NA8320J834 (Eptifibatide)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/drug therapy/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - *Electrocardiography
MH  - Endothelium, Vascular/metabolism
MH  - Eptifibatide
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Infusions, Intravenous
MH  - P-Selectin/*blood
MH  - Peptides/administration & dosage/*therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Treatment Outcome
MH  - von Willebrand Factor/*metabolism
EDAT- 2008/02/12 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/02/12 09:00
PHST- 2008/02/12 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/02/12 09:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2007;47(6):4-9.